GlassScriptPhysician profile
Richard Berger
NPI 1992462758
$5,989.16
in general payments reported to CMS, 2019-2025
27 companies · $2,280 in 2025
The $2,280 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $393 · 2023: $1,195 · 2024: $2,122 · 2025: $2,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,793 · Travel and Lodging: $704 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,792.52 |
| Travel and Lodging | $704.08 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,294.75 | 2022-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $1,000.24 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $904.09 | 2024-2025 | Inspire |
| Genzyme Corporation | $750.79 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $480.28 | 2022-2025 | Dupixent |
| Amgen INC. | $331.06 | 2022-2025 | Tezspire |
| Philips North America LLC | $185.89 | 2022-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $168.97 | 2022-2025 | Aralast |
| Genentech USA, INC. | $103.97 | 2023-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Harmony Biosciences LLC | $90.53 | 2022-2025 | Wakix |
| Verona Pharma, INC. | $88.62 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.43 | 2024-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $60.69 | 2024-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $55.40 | 2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $51.93 | 2024 | |
| Insmed, INC. | $51.44 | 2024-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $30.59 | 2025 | Opsumit, Uptravi |
| Jazz Pharmaceuticals INC. | $30.30 | 2024-2025 | |
| Electromed, INC. | $25.41 | 2023 | Smartvest |
| Baxter Healthcare | $20.42 | 2023 | Hillrom - Life 2000 Ventilation System |
| Phadia US INC. | $18.70 | 2025 | Immunocap |
| Azurity Pharmaceuticals, INC. | $18.48 | 2025 | Alvesco |
| Axsome Therapeutics, INC. | $16.63 | 2023 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $16.31 | 2023 | Lumryz |
| United Therapeutics Corporation | $15.60 | 2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.